PHARMACOKINETICS OF NEW CEPHALOSPORINS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。不断需要新的抗生素来治疗具有抗生素耐药性的生物体感染。需要对头孢菌素在黑猩猩体内的生物利用度进行测试，因为人类和黑猩猩体内存在一种限制其生物利用度的血清结合蛋白。因此，一项在黑猩猩身上进行的药代动力学研究预测了启动人体试验所使用的抗生素水平。这项拟议的实验将涉及在2只体重相近的同性黑猩猩身上测试4种新的头孢菌素化合物。复方将每两周静脉注射一次，剂量为0.5毫克/公斤。每次剂量将包括以下血液采样时间：0或在剂量之前的15分钟、30分钟、1小时、2小时、4小时、8小时。和24小时。将对血浆样本进行药物水平测试，以确定这些新药的药代动力学。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. New antibiotics are constantly needed to treat infections with antibiotic resistant organisms. Cephalosporins need to be tested for bioavailability in chimpanzees, because there is a serum binding protein in humans and chimpanzees that limits availability. Thus, a pharmacokinetic study in chimpanzees predicts the level of antibiotic with which to initiate human trials. The proposed experiment will involve testing of 4 new cephalosporin compounds in 2 same-sex chimpanzees of similar weight. Compounds will be given IV every two weeks at a dose of 0.5 mg/kg. each dosing will involve the following blood sampling times; 0 or immediately prior to the dose, 15 min., 30 min., 1 hr., 2 hrs., 4 hrs., 8 hrs. and 24 hrs. Plasma samples will be tested for drug levels to determine the pharmacokinetics of these new drugs.